Progress of CAR -NK cell therapy in hematological tumors
10.3760/cma.j.cn115356-20230513-00109
- VernacularTitle:CAR-NK疗法在血液肿瘤中的应用进展
- Author:
Rubing ZHENG
1
;
Yi XIAO
Author Information
1. 华中科技大学同济医学院附属同济医院血液科，武汉 430030
- Keywords:
Lymphoma, extranodal NK-T-cell;
Immunotherapy;
Chimeric antigen receptor T-cells
- From:
Journal of Leukemia & Lymphoma
2024;33(9):569-573
- CountryChina
- Language:Chinese
-
Abstract:
The treatment methods of tumors are usually surgical therapy, chemotherapy, radiotherapy and immunotherapy, but hematologic tumors are difficult to cure and have a poor prognosis due to the characteristics of systemic invasion and easy recurrence. In recent years, cellular immunotherapy has been widely recognized for its excellent efficacy in the treatment of hematologic tumors. Chimeric antigen receptor (CAR) T-cell immunotherapy is developing rapidly, which has changed the traditional approach to the treatment of hematologic tumors and improved the prognosis of patients to some extent. However, its clinical application is limited by many adverse reactions. Natural killer (NK) cells are a part of the innate immune system and are the first line of defense against infections and tumors. Compared to T cells, CAR-NK cells can recognize a variety of antigens, have better safety, the increased proliferation capacity, and are more durable in vivo, exhibit stronger cell killing effects, and are feasible for "off-the-shelf" production. This article briefly reviews the recent application progress of CAR-NK cell therapy in the treatment of hematologic tumors.
